| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8707763 | Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology | 2018 | 23 Pages |
Abstract
Health care providers should be aware of the possibility of MRONJ associated with the TT agents sunitinib, everolimus, and dasatinib and uncommon cancer types, including renal cell carcinoma, non-small-cell lung cancer, glioblastoma, and leukemia, where MRONJ may also occur.
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Hoda DDS, Charlotte Emilie Nor MPH, Morten DDS, DrOdont,